Nuveen Asset Management, LLC Sage Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 142,694 shares of SAGE stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

142,694

Previous 142,694 -0.0%

Holding current value

$1.04 Million

Previous $1.03 Million 24.71%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $22,554 - $29,360	1,319 Added 0.93%	142,694 $3.09 Million
Q3 2023 Nov 14, 2023	SELL	$16.75 - $48.98 $2.88 Million - $8.43 Million	-172,074 Reduced 54.9%	141,375 $2.91 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $7.06 Million - $10.3 Million	173,664 Added 124.24%	313,449 $14.7 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $661,766 - $826,896	-17,756 Reduced 11.27%	139,785 $5.87 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $821,164 - $1.11 Million	-25,502 Reduced 13.93%	157,541 $6.01 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $124,245 - $166,546	-3,849 Reduced 2.06%	183,043 $7.17 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $1.09 Million - $1.51 Million	-39,711 Reduced 17.52%	186,892 $6.04 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $645,247 - $960,412	-21,011 Reduced 8.49%	226,603 $7.61 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $465,584 - $591,842	12,563 Added 5.34%	247,614 $10.5 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $346,517 - $493,783	8,607 Added 3.8%	235,051 $10.4 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $2.58 Million - $3.72 Million	46,976 Added 26.18%	226,444 $12.9 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $3.03 Million - $4.14 Million	-42,832 Reduced 19.27%	179,468 $13.4 Million
Q4 2020 May 17, 2021	BUY	$58.41 - $89.06 $1.99 Million - $3.04 Million	34,104 Added 18.12%	222,300 $19.2 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $3.83 Million - $5.84 Million	-65,555 Reduced 25.83%	188,196 $16.3 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $1.1 Million - $1.67 Million	-26,684 Reduced 9.52%	253,751 $15.5 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $2.04 Million - $3.39 Million	-78,568 Reduced 21.89%	280,435 $11.7 Million
Q1 2020 May 14, 2020	SELL	$26.15 - $77.24 $4.46 Million - $13.2 Million	-170,727 Reduced 32.23%	359,003 $10.3 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $3.46 Million - $8.9 Million	57,482 Added 12.17%	529,730 $38.2 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $20.9 Million - $28.3 Million	-149,177 Reduced 24.01%	472,248 $66.3 Million
Q2 2019 Aug 15, 2019	BUY	$157.85 - $183.09 $98.1 Million - $114 Million	621,425 New	621,425 $114 Million
Q3 2018 Nov 13, 2018	SELL	$138.11 - $169.04 $747,313 - $914,675	-5,411 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $750,504 - $939,788	-5,347 Reduced 49.7%	5,411 $847,000
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $295,779 - $373,889	1,944 Added 22.06%	10,758 $1.73 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $34,671 - $95,551	-571 Reduced 6.08%	8,814 $0
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $576,239 - $830,760	9,385	9,385 $585,000

Others Institutions Holding SAGE

# of Institutions

194

Shares Held

45M

Call Options Held

304K

Put Options Held

117K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $434M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Sage Therapeutics, Inc. Transaction History